Effects of a novel Hungarian antacid containing Al and Mg (Tisacid®) on mucosal prostaglandin generation and oxygen free radicals in normal rats

L. Nagy, G. Mózsik, A. Vincze, G. Sütö, B. Hunyady, J. Rinfel, T. Past, T. Javor

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A new patented chemical agent (Al-Mag-hydroxy-carbonate; acid-binding capacity > 30 mmol/g) was produced by our work-team. After our preliminary pharmacological and some prospective, randomized, multicentre, controlled clinical studies, this antacid was registered (Tisacid® tablet and suspension; Alkaloida, Hungary). A cumulative ulcer healing rate of 80-85% was proved by Tisacid monotherapy applied in low doses (from 80 to 160 mmol/day) in patients with duodenal ulcer. The aims of this study were: (i) to determine the role of different antacids on the genesis of mucosal prostaglandins (PGs) (PGE2 and 6-keto-PGF1α) in normal rats; (ii) to evaluate the effects of indomethacin pre-treatment (20 mg/kg b.w., s.c.) on the Tisacid-induced alterations of gastric mucosal PG-contents; (iii) to analyse the generation of oxygen free radicals and lipid peroxidation in the rat oxyntic mucosa by the application of different doses of Tisacid (activities of CAT, GSH-px and SOD, contents of MDA and red. GSH). It was found that: Tisacid has a potent gastroprotective effect in gastric mucosa, via (a) an increase in the mucosal levels of PGs, and (b) a scavenging-like effect in normal rat gastric mucosa. It is concluded that the gastroprotective effect of Tisacid appears because of the following: (i) excellent acid-neutralizing capacity; (ii) mucosal generation of PGs (PGE2 and PGI2); (iii) free radical scavenging; (iv) its possible activity as a Ca-antagonist (Mg-containing compound).

Original languageEnglish
Pages (from-to)197-203
Number of pages7
JournalDrugs under Experimental and Clinical Research
Volume16
Issue number4
Publication statusPublished - 1990

Fingerprint

Antacids
Free Radicals
Prostaglandins
Reactive Oxygen Species
Gastric Mucosa
Dinoprostone
Acids
Hungary
Carbonates
Epoprostenol
Duodenal Ulcer
Indomethacin
Lipid Peroxidation
Tablets
Ulcer
Stomach
Suspensions
Mucous Membrane
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

@article{0ab7a22de6914122a82d5cbdf7bd7445,
title = "Effects of a novel Hungarian antacid containing Al and Mg (Tisacid{\circledR}) on mucosal prostaglandin generation and oxygen free radicals in normal rats",
abstract = "A new patented chemical agent (Al-Mag-hydroxy-carbonate; acid-binding capacity > 30 mmol/g) was produced by our work-team. After our preliminary pharmacological and some prospective, randomized, multicentre, controlled clinical studies, this antacid was registered (Tisacid{\circledR} tablet and suspension; Alkaloida, Hungary). A cumulative ulcer healing rate of 80-85{\%} was proved by Tisacid monotherapy applied in low doses (from 80 to 160 mmol/day) in patients with duodenal ulcer. The aims of this study were: (i) to determine the role of different antacids on the genesis of mucosal prostaglandins (PGs) (PGE2 and 6-keto-PGF1α) in normal rats; (ii) to evaluate the effects of indomethacin pre-treatment (20 mg/kg b.w., s.c.) on the Tisacid-induced alterations of gastric mucosal PG-contents; (iii) to analyse the generation of oxygen free radicals and lipid peroxidation in the rat oxyntic mucosa by the application of different doses of Tisacid (activities of CAT, GSH-px and SOD, contents of MDA and red. GSH). It was found that: Tisacid has a potent gastroprotective effect in gastric mucosa, via (a) an increase in the mucosal levels of PGs, and (b) a scavenging-like effect in normal rat gastric mucosa. It is concluded that the gastroprotective effect of Tisacid appears because of the following: (i) excellent acid-neutralizing capacity; (ii) mucosal generation of PGs (PGE2 and PGI2); (iii) free radical scavenging; (iv) its possible activity as a Ca-antagonist (Mg-containing compound).",
author = "L. Nagy and G. M{\'o}zsik and A. Vincze and G. S{\"u}t{\"o} and B. Hunyady and J. Rinfel and T. Past and T. Javor",
year = "1990",
language = "English",
volume = "16",
pages = "197--203",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of a novel Hungarian antacid containing Al and Mg (Tisacid®) on mucosal prostaglandin generation and oxygen free radicals in normal rats

AU - Nagy, L.

AU - Mózsik, G.

AU - Vincze, A.

AU - Sütö, G.

AU - Hunyady, B.

AU - Rinfel, J.

AU - Past, T.

AU - Javor, T.

PY - 1990

Y1 - 1990

N2 - A new patented chemical agent (Al-Mag-hydroxy-carbonate; acid-binding capacity > 30 mmol/g) was produced by our work-team. After our preliminary pharmacological and some prospective, randomized, multicentre, controlled clinical studies, this antacid was registered (Tisacid® tablet and suspension; Alkaloida, Hungary). A cumulative ulcer healing rate of 80-85% was proved by Tisacid monotherapy applied in low doses (from 80 to 160 mmol/day) in patients with duodenal ulcer. The aims of this study were: (i) to determine the role of different antacids on the genesis of mucosal prostaglandins (PGs) (PGE2 and 6-keto-PGF1α) in normal rats; (ii) to evaluate the effects of indomethacin pre-treatment (20 mg/kg b.w., s.c.) on the Tisacid-induced alterations of gastric mucosal PG-contents; (iii) to analyse the generation of oxygen free radicals and lipid peroxidation in the rat oxyntic mucosa by the application of different doses of Tisacid (activities of CAT, GSH-px and SOD, contents of MDA and red. GSH). It was found that: Tisacid has a potent gastroprotective effect in gastric mucosa, via (a) an increase in the mucosal levels of PGs, and (b) a scavenging-like effect in normal rat gastric mucosa. It is concluded that the gastroprotective effect of Tisacid appears because of the following: (i) excellent acid-neutralizing capacity; (ii) mucosal generation of PGs (PGE2 and PGI2); (iii) free radical scavenging; (iv) its possible activity as a Ca-antagonist (Mg-containing compound).

AB - A new patented chemical agent (Al-Mag-hydroxy-carbonate; acid-binding capacity > 30 mmol/g) was produced by our work-team. After our preliminary pharmacological and some prospective, randomized, multicentre, controlled clinical studies, this antacid was registered (Tisacid® tablet and suspension; Alkaloida, Hungary). A cumulative ulcer healing rate of 80-85% was proved by Tisacid monotherapy applied in low doses (from 80 to 160 mmol/day) in patients with duodenal ulcer. The aims of this study were: (i) to determine the role of different antacids on the genesis of mucosal prostaglandins (PGs) (PGE2 and 6-keto-PGF1α) in normal rats; (ii) to evaluate the effects of indomethacin pre-treatment (20 mg/kg b.w., s.c.) on the Tisacid-induced alterations of gastric mucosal PG-contents; (iii) to analyse the generation of oxygen free radicals and lipid peroxidation in the rat oxyntic mucosa by the application of different doses of Tisacid (activities of CAT, GSH-px and SOD, contents of MDA and red. GSH). It was found that: Tisacid has a potent gastroprotective effect in gastric mucosa, via (a) an increase in the mucosal levels of PGs, and (b) a scavenging-like effect in normal rat gastric mucosa. It is concluded that the gastroprotective effect of Tisacid appears because of the following: (i) excellent acid-neutralizing capacity; (ii) mucosal generation of PGs (PGE2 and PGI2); (iii) free radical scavenging; (iv) its possible activity as a Ca-antagonist (Mg-containing compound).

UR - http://www.scopus.com/inward/record.url?scp=0025048656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025048656&partnerID=8YFLogxK

M3 - Article

C2 - 2076656

AN - SCOPUS:0025048656

VL - 16

SP - 197

EP - 203

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 4

ER -